Skip To Main Content

About Antibody Drug Conjugates

Combining the selectivity of monoclonal antibodies with potent cytotoxic agents

Antibody drug conjugate (ADC) technology leverages the selectivity of monoclonal antibodies (MAbs) to offer novel possibilities to cancer patients.1 This approach has been utilized in the management of select hematologic malignancies and solid tumors.1,2

ADCs can be an effective and targeted vehicle designed to deliver potent cytotoxic agents directly to tumor cells through selective antibody binding.3

Antibody Drug Conjugates

ADCs are a rational vehicle to exploit the internalization of monoclonal antibodies for the delivery of a potent cytotoxic agent inside target cells.3,4

This technology may be applied as foundational ADC therapy or as a potential complement to existing treatment approaches.1

Genentech is currently investigating the potential of using an ADC with other agents such as traditional monoclonal antibodies, including PD-L1 inhibitors, small molecules, and T-cell bispecific antibodies.5,6

    • Diamantis N, Banerji U. Br J Cancer. 2016;114:362-367. PMID: 26742008

      Diamantis N, Banerji U. Br J Cancer. 2016;114:362-367. PMID: 26742008

    • Pfeifer M, Zheng B, Erdmann T, et al. Leukemia. 2015;29:1578-1586. PMID: 25708834

      Pfeifer M, Zheng B, Erdmann T, et al. Leukemia. 2015;29:1578-1586. PMID: 25708834

    • Peters C, Brown S. Biosci Rep. 2015;35. pii: e00225. PMID: 26182432

      Peters C, Brown S. Biosci Rep. 2015;35. pii: e00225. PMID: 26182432

    • Polson AG, Yu S-F, Elkins K, et al. Blood. 2007;110:616-623. PMID: 17374736

      Polson AG, Yu S-F, Elkins K, et al. Blood. 2007;110:616-623. PMID: 17374736

    • Roche. 2023 Q1 results. April 26, 2023. Accessed May 10, 2023. https://assets.cwp.roche.com/f/126832/x/469b6bc1c5/irp230426-a.pdf

      Roche. 2023 Q1 results. April 26, 2023. Accessed May 10, 2023. https://assets.cwp.roche.com/f/126832/x/469b6bc1c5/irp230426-a.pdf

    • US National Institutes of Health. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03671018. Accessed May 26, 2022.

      US National Institutes of Health. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03671018. Accessed May 26, 2022.

    Microscope icon

    Discover cancer biomarkers

    Learn more about the importance of oncologic biomarkers and what they can tell you.

    Molecular pathways icon

    Explore molecular pathways

    Learn more about how cancer avoids immune response.